Name: Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3 (Video) | JoVE Journal
Uploaded: 2023-04-07T14:00:00.000+00:00
Duration: 8 min 36 s
Description: Learn a scalable synthesis protocol for the Upatinib intermediate ACT051-3 using optimized reaction conditions. This method offers a simple, cost-effective, and environmentally friendly approach for pharmaceutical production.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

There are no acknowledgments to mention here.

1. Pilot scale synthesis of compounds ACT051-2 and ACT051-3
<ol>
	<li>Synthesis of 2-bromo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine (ACT051-2)
	<ol>
		<li>In a round-bottom flask, dissolve 50.0 g of the compound 2-bromo-5H-pyrrolo[2,3-b]pyrazine (ACT051-1; 0.25 M) in 15 mL of N,N-dimethylformamide (DMF; 3 V).</li>
		<li>Add 65.3 g of diisopropylethylamine (DIPEA; 0.51 M) to the reaction solution under nitrogen protection (provide a gas and moisture barrier) and cool the temperature to 0-5 &#176;C through a cool water bath. For nitrogen protection, pump the pressure of the reactor to -0.75--0.8 MPa, then pass N2 to balance the pressure at 0.1 MPa.</li>
		<li>Add 60.20 g of TsCl dissolved in 12 mL of DMF (0.32 M). Raise the temperature to 20-30 &#176;C through the warm water bath and stir for about 1 h. Add cool water (600.0 mL, 0-10 &#176;C) to the mixture and stir for another 1 h.</li>
		<li>Filter the product under a vacuum using a glass funnel with a sanding board padded with filter paper. Wash with water (200.0 mL) several times and dry using an electric thermostatic drying oven to obtain a pale-yellow solid (ACT051-2) with a yield of 78%.</li>
	</ol>
	</li>
	<li>Synthesis of tert-butyl (5-toluenesulfonyl-5H-pyrrole [2,3-b] pyrazine-2-yl) carbamate (ACT051-3)
	<ol>
		<li>Dissolve 176.11 g of ACT051-2 in 366.31 g of 1,4-dioxane in a three-port round-bottom flask.</li>
		<li>Add 65.75 g of tert-butyl carbamate, 138.21 g of granular potassium carbonate (2.0 eq), 11.57 g of xantphos (0.04 eq), and 2.25 g of Pd(OAc)2 (1.28% wt) to the solution.</li>
		<li>Heat the mixture to 105 &#176;C and stir for 7 h under a nitrogen atmosphere. Allow the mixture to cool to room temperature and filter the product with a Buchner funnel (the filter paper aperture is 80-120 &#181;m).</li>
		<li>Wash the filter residue with ethyl acetate (200 mL). Use a circulating water vacuum pump to concentrate the product under reduced pressure at 50-60 &#176;C with a pressure value of -0.095 MPa. Keep the pump working to maintain the pressure and obtain a dark brown oil.</li>
		<li>Purify the crude product with column chromatography, eluting with petroleum ether and ethyl acetate (V/V, 10/1) to obtain the target compound as a white solid with a yield of 93.5%.</li>
	</ol>
	</li>
</ol>
2. Pilot scale-up synthesis of compounds ACT051-2 and ACT051-3
<ol>
	<li>Pilot scale-up synthesis of 2-bromo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine (ACT051-2)
	<ol>
		<li>Add 1.0 kg of ACT051-1 (5.05 M) and 1.305 kg of DIPEA (10.1 M) to a three-port round-bottom flask. Add 3 L of DMF (3 V) to the flask and dissolve the solid. Heat the reaction mixture to 35 &#176;C.</li>
		<li>Add 1.203 kg of TsCl (6.31 M) to the reaction solution and stir for 1 h. Stir the mixture until the completion of the reaction is confirmed by thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC). In brief, take a small amount of reaction product and subject this to TLC monitoring. When the TLC shows that there is almost no raw material left, send the sample to the HPLC central control, and detect the reaction to raw material or the product ratio to be 0.1/99.9.</li>
		<li>Pour in 8.4 L of cool water and stir for another 0.5 h. Filter all liquids with a Buchner funnel (the filter paper aperture is 80-120 &#181;m) and rinse the crude product with 600 mL of water.</li>
		<li>Dry the resulting product at 70 &#176;C overnight using an electric thermostatic drying oven and obtain a product with a yield of 94.9%.</li>
	</ol>
	</li>
	<li>Pilot scale-up synthesis of tert-butyl (5-toluenesulfonyl-5H-pyrrole [2,3-b] pyrazine-2-yl) carbamate (ACT051-3)
	<ol>
		<li>Add 3.31 L of tert-amyl alcohol and 4.97 L of toluene (V/V, 2/3) to the reaction kettle.</li>
		<li>To the solution, add 1.66 kg of ACT051-2, 0.83 kg of tert-butyl carbamate, 1.301 kg of powdered potassium carbonate, 0.11 kg of xantphos, and 0.31 kg of DIPEA.</li>
		<li>Evacuate nitrogen three times, as in step 1.1.2, repeat this 3x, and add 10 g of Pd(OAc)2 (0.60% wt) to the reaction solution under nitrogen protection.</li>
		<li>Heat the reaction mixture to 90 &#176;C and stir for 4 h. Cool the mixture to 40 &#176;C or below.</li>
		<li>Filter the reaction solution with a Buchner funnel (the filter paper aperture is 80-120 &#181;m) using diatomite as a filter aid and washing the filter cake with toluene.</li>
		<li>Collect and concentrate the filtrate. Use a circulating water vacuum pump to concentrate the filtrate under reduced pressure at 50-60 &#176;C with a pressure value of -0.095 MPa. Keep the pump working to maintain the pressure.</li>
		<li>Add 300 mL of heptane and stir for 20 min. Filter the reaction solution again with a Buchner funnel (the filter paper aperture is 80-120 &#181;m) and rinse the crude product with heptane (50 mL, three times). Dry and obtain the product with a yield of 96.3%.</li>
	</ol>
	</li>
</ol>
3. Industrial production of compounds ACT051-2 and ACT051-3
<ol>
	<li>Industrial production of 2-bromo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine (ACT051-2)
	<ol>
		<li>Confirm that the reactor is clean and free of water, and make sure the mixing device makes no noise when turning on and the bottom discharge valve of the reactor has been closed.</li>
		<li>Add 355.50 kg of DMF (3 V) into the 2,000 L enamel reactor and start to stir. Add 125.04 kg of ACT051-1 (1.0 eq) and 164.8 kg of DIPEA (2.0 eq) to the solution.</li>
		<li>Drop the temperature to 20-25 &#176;C under nitrogen protection. Add 150.22 kg of TsCl (1.25 eq) at 25-35 &#176;C in 10 batches within 3 h.</li>
		<li>Allow the mixture to remain at 25-35 &#176;C and stir for 2 h. Prepare 750.20 kg of cool water (3-4 &#176;C) in another 2,000 L reactor.</li>
		<li>Monitor the reaction by HPLC and confirm completion of the reaction when the remaining raw material is 0.5%.</li>
		<li>Add the cool water ( 3-4 &#176;C) to the reaction mixture and stir at 15-30 &#176;C for 1.5 h. Collect the filtrate and rinse with water (250-500 kg, 2-4 V) until it becomes neutral (tested using pH paper).</li>
		<li>Dry the product at 60-65 &#176;C for 30.5 h to obtain a light brown solid with a yield of 95.5%.</li>
	</ol>
	</li>
	<li>Industrial production of tert-butyl (5-toluenesulfonyl-5H-pyrrole [2,3-b] pyrazine-2-yl) carbamate (ACT051-3)
	<ol>
		<li>Confirm the reactor is clean and free of water, and make sure the mixing device is normal and the bottom discharge valve of the reactor has been closed.</li>
		<li>Add 340.10 kg of tert-amyl alcohol (2 V) and 552.50 kg of toluene (3 V) into a 2,000 L enamel reactor and start to stir.</li>
		<li>Add 212.40 kg of ACT051-2 (1.0 eq), 106.00 kg of tert-butyl carbamate (1.5 eq), 166.70 kg of powdered potassium carbonate (2.0 eq), 14.10 kg of xantphos (0.04 eq), 39.40 kg of DIPEA (0.5 eq), and 1.06 kg of Pd(OAc)2 (0.5% wt) to the solution.</li>
		<li>Replace the nitrogen four times, allow the mixture to heat to 85-95 &#176;C under nitrogen protection, and stir for 3 h. Monitor the reaction by HPLC and confirm completion of the reaction when the remaining raw material is 0.44%.</li>
		<li>Cool the reaction temperature to 20-30 &#176;C. Collect the solution in batches and place it in a 125 L plastic bucket for 30 min.</li>
		<li>Filter the reaction solution with a chemical suction filter barrel (the filter bag aperture is 10-15 &#181;m) using diatomite as a filter aid and washing the filter cake with toluene (185.20-370.40 kg, 1-2 V).</li>
		<li>Collect the filtrate in an enamel vessel and use a circulating water vacuum pump under reduced pressure at 55-65 &#176;C for 10 h with a pressure value of -0.095 MPa. Keep the pump working to maintain the pressure and obtain the product compound as a viscous liquid.</li>
		<li>Evaporate the product twice by pumping toluene and continuing the reaction. Concentrate the final product for 4 h. Purify the resulting product with column chromatography, eluting with heptane and ethyl acetate (V/V, 10/1-3/1), to obtain a solid with a yield of 98.5%.</li>
	</ol>
	</li>
</ol>

<ol><li>Kerschbaumer, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Points+to+consider+for+the+treatment+of+immune-mediated+inflammatory+diseases+with+Janus+kinase+inhibitors%3A+a+systematic+literature+research%5BTitle%5D)+AND+%22RMD+Open%22%5BJournal%5D)">Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.</a> RMD Open. 6 (3), e001374(2020).</li>
<li>Fragoulis, G. E., Brock, J., Basu, N., McInnes, I. B., Siebert, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+for+JAK+inhibitors+in+the+treatment+of+immune-+mediated+rheumatic+and+related+conditions%5BTitle%5D)+AND+%22The+Journal+of+Allergy+and+Clinical+Immunology%22%5BJournal%5D)">The role for JAK inhibitors in the treatment of immune- mediated rheumatic and related conditions.</a> The Journal of Allergy and Clinical Immunology. 148 (4), 941-952 (2021).</li>
<li>Shaw, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((P220+Long-term+safety+profile+of+upadacitinib+in+patients+with+rheumatoid+arthritis%2C+psoriatic+arthritis%2C+or+ankylosing+spondylitis%5BTitle%5D)+AND+%22Rheumatology%22%5BJournal%5D)">P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.</a> Rheumatology. 61, 133(2022).</li>
<li>Keeling, S., Maksymowych, W. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((JAK+inhibitors%2C+psoriatic+arthritis%2C+and+axial+spondyloarthritis%3A+a+critical+review+of+clinical+trials%5BTitle%5D)+AND+%22Expert+Review+of+Clinical+Immunology%22%5BJournal%5D)">JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.</a> Expert Review of Clinical Immunology. 17 (7), 701-715 (2021).</li>
<li>Fleischmann, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Safety+and+efficacy+of+elsubrutinib+or+upadacitinib+alone+or+in+combination+%28ABBV-599%29+in+patients+with+rheumatoid+arthritis+and+inadequate+response+or+intolerance+to+biological+therapies%3A+a+multicentre%2C+double-blind%2C+randomised%2C+controlled%2C+phase+2+trial%5BTitle%5D)+AND+%22The+Lancet+Rheumatology%22%5BJournal%5D)">Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.</a> The Lancet Rheumatology. 4 (6), e395-e406 (2022).</li>
<li>Stamatis, P., Bogdanos, D. P., Sakka, L. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Upadacitinib+tartrate+in+rheumatoid+arthritis%5BTitle%5D)+AND+%22Drugs+of+Today%22%5BJournal%5D)">Upadacitinib tartrate in rheumatoid arthritis.</a> Drugs of Today. 56 (11), 723-732 (2020).</li>
<li>Rubbert-Roth, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Trial+of+upadacitinib+or+abatacept+in+rheumatoid+arthritis%5BTitle%5D)+AND+%22The+New+England+Journal+of+Medicine%22%5BJournal%5D)">Trial of upadacitinib or abatacept in rheumatoid arthritis.</a> The New England Journal of Medicine. 383 (16), 1511-1521 (2020).</li>
<li>Asfour, L., Getsos Colla, T., Moussa, A., Sinclair, R. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Concurrent+chronic+alopecia+areata+and+severe+atopic+dermatitis+successfully+treated+with+upadacitinib%5BTitle%5D)+AND+%22International+Journal+of+Dermatology%22%5BJournal%5D)">Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib.</a> International Journal of Dermatology. 61 (11), e416-e417 (2022).</li>
<li>Cantelli, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Upadacitinib+improved+alopecia+areata+in+a+patient+with+atopic+dermatitis%3A+A+case+report%5BTitle%5D)+AND+%22Dermatologic+Therapy%22%5BJournal%5D)">Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report.</a> Dermatologic Therapy. 35 (4), e15346(2022).</li>
<li>Traves, P. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((JAK+selectivity+and+the+implications+for+clinical+inhibition+of+pharmacodynamic+cytokine+signalling+by+filgotinib%2C+upadacitinib%2C+tofacitinib+and+baricitinib%5BTitle%5D)+AND+%22Annals+of+the+Rheumatic+Diseases%22%5BJournal%5D)">JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.</a> Annals of the Rheumatic Diseases. 80 (7), 865-875 (2021).</li>
<li>Rozema, M. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+a+scalable+enantioselective+synthesis+of+JAK+inhibitor+upadacitinib%5BTitle%5D)+AND+%22Organic+Process+Research+%26+Development%22%5BJournal%5D)">Development of a scalable enantioselective synthesis of JAK inhibitor upadacitinib.</a> Organic Process Research & Development. 26 (3), 949-962 (2022).</li>
<li>Wynn, J. P., Hanchar, R., Kleff, S., Senyk, D., Tiedje, T. Biobased technology commercialization: the importance of lab to pilot scale-up. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aWynn%2C+JP+%22Metabolic+Engineering+for+Bioprocess+Commercialization%22">Metabolic Engineering for Bioprocess Commercialization</a>. , Springer. 101-119 (2016).</li>
<li>Tang, C., et al. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aTang%2C+C+%22Influenza+virus+replication+inhibitor+and+use+thereof%22">Influenza virus replication inhibitor and use thereof</a>. , US202000283454A1 (2020).</li>
<li>Ren, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inhibitors+of+influenza+virus+replication+and+uses+thereof%5BTitle%5D)+AND+%22Center+for+Biotechnology+Information%22%5BJournal%5D)">Inhibitors of influenza virus replication and uses thereof.</a> Center for Biotechnology Information. , US20200339564A1 (2020).</li>
<li>Van Epps, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Design+and+synthesis+of+tricyclic+cores+for+kinase+inhibition%5BTitle%5D)+AND+%22Bioorganic+%26+Medicinal+Chemistry+Letters%22%5BJournal%5D)">Design and synthesis of tricyclic cores for kinase inhibition.</a> Bioorganic & Medicinal Chemistry Letters. 23 (3), 693-698 (2013).</li>
<li>Paul, F., Patt, J., Hartwig, J. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Palladium-catalyzed+formation+of+carbon-nitrogen+bonds.+Reaction+intermediates+and+catalyst+improvements+in+the+hetero+cross-coupling+of+aryl+halides+and+tin+amides%5BTitle%5D)+AND+%22Journal+of+the+American+Chemical+Society%22%5BJournal%5D)">Palladium-catalyzed formation of carbon-nitrogen bonds. Reaction intermediates and catalyst improvements in the hetero cross-coupling of aryl halides and tin amides.</a> Journal of the American Chemical Society. 116 (13), 5969-5970 (1994).</li>
<li>Zhou, T., Ji, C. L., Hong, X., Szostak, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Palladium-catalyzed+decarbonylative+Suzuki-Miyaura+cross-coupling+of+amides+by+carbon-nitrogen+bond+activation%5BTitle%5D)+AND+%22Chemical+Science%22%5BJournal%5D)">Palladium-catalyzed decarbonylative Suzuki-Miyaura cross-coupling of amides by carbon-nitrogen bond activation.</a> Chemical Science. 10 (42), 9865-9871 (2019).</li>
<li>Sain, S., Jain, S., Srivastava, M., Vishwakarma, R., Dwivedi, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Application+of+palladium-catalyzed+cross-coupling+reactions+in+organic+synthesis%5BTitle%5D)+AND+%22Current+Organic+Synthesis%22%5BJournal%5D)">Application of palladium-catalyzed cross-coupling reactions in organic synthesis.</a> Current Organic Synthesis. 16 (8), 1105-1142 (2019).</li>
<li>Takale, B. S., Kong, F. Y., Thakore, R. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recent+applications+of+Pd-catalyzed+Suzuki-Miyaura+and+Buchwald-Hartwig+couplings+in+pharmaceutical+process+chemistry%5BTitle%5D)+AND+%22Organics%22%5BJournal%5D)">Recent applications of Pd-catalyzed Suzuki-Miyaura and Buchwald-Hartwig couplings in pharmaceutical process chemistry.</a> Organics. 3 (1), 1-21 (2021).</li>
</ol>

The authors have nothing to disclose.

The reaction conditions of synthesis, including reaction temperature, time, the selection of reaction reagents, and the ratio of materials, affect the feasibility of the reaction, yields, purity, and production cost, especially for scale-up production.
In the laboratory synthesis of ACT051-2, TsCl in liquid form (dissolved in DMF; step 1.1.3) can be used to in the reaction; however, it is not suitable for pilot scale-up synthesis or industrial production, as using liquid TsCl for this reaction...

Upatinib has become a globally popular Janus kinase 1 (JAK1) inhibitor for treating immune disorders in recent years1,2. This drug has demonstrated significant therapeutic effects on psoriaticarthritis (PsA)3,4, rheumatoid arthritis (RA)5,6,7, and atopic dermatitis (AD)8,9. Additionally, due to its high selectivity10, Upatinib has a wide range of clinical applications. Tert-butyl (5-tosyl-5h-pyrolo [2,3-b] pyrazin-2-yl) carbamate (ACT051-3) is an important intermediate of Upatinib. Its main structural components are the pyrrole ring and the pyrazine ring, which can be used in the preparation of new nitrogen-containing tricyclic kinase inhibitors for the treatment of immune and tumor diseases11.
Pilot scale-up is a medium-sized scale-up (50x-100x) of the process route and conditions determined by the laboratory pilot study, followed by process testing, industrial investigation, and optimization to determine the best industrial production and operating conditions12.
At present, the lab synthesis routes for this intermediate compound (ACT051-3) have been reported, but they have only been performed on a small scale due to problems of low yield, complex reactions, and high equipment requirements, which still have a lot of room to be optimized11,13,14,15. However, no process route has been reported for pilot scale-up and industrial production of the intermediate compound ACT051-3 at present.
Therefore, in this study, we investigated the pilot scale-up and production route of the compound ACT051-3, with reference to the better reported laboratory synthetic routes. Compared with the original laboratory synthesis route, many appropriate adjustments and improvements were made to the reaction conditions, and other factors that may affect the reaction results were investigated. Finally, the most suitable process parameters for the optimal route were identified, and we obtained a process route that is simple to operate, low cost, and environmentally friendly, which is suitable for the pilot scale-up and production of ACT051-3.

<table><tbody><tr><td>2-bromo-5H-pyrrolo[2,3-b]pyrazine</td><td>Nanjing Cook Biotechnology Co., Ltd.</td><td>19120110</td><td></td></tr><tr><td>1,4-dioxane</td><td>Liaoning cook Biotechnology Co., Ltd</td><td>General Reagent</td><td></td></tr><tr><td>1H NMR</td><td></td><td>Bruker AVIII 500</td><td></td></tr><tr><td>37% chloride acid molecular grade</td><td>NEON</td><td>02618 NEON</td><td></td></tr><tr><td>4-toluenesulfonyl chloride (TsCl)</td><td>Nanjing Cook Biotechnology Co., Ltd.</td><td>AR A2010137</td><td></td></tr><tr><td>Anti-Chicken IgY (H+L), highly cross-adsorbed, CF&amp;nbsp;488A antibody produced in donkey</td><td>Sigma-Aldrich</td><td>SAB4600031</td><td></td></tr><tr><td>Anti-mouse IgG (H+L), F(ab&amp;prime;)2</td><td>Sigma-Aldrich</td><td>SAB4600388</td><td></td></tr><tr><td>BD FACSCanto II</td><td>BD Biosciences</td><td>BF-FACSC2</td><td></td></tr><tr><td>BD FACSDiva CS&amp;amp;T research beads (CS&amp;amp;T research beads)</td><td>BD Biosciences</td><td>655050</td><td></td></tr><tr><td>BD FACSDiva software 7.0</td><td>BD Biosciences</td><td>655677</td><td></td></tr><tr><td>Bovine serum albumin</td><td>Sigma-Aldrich</td><td>A4503</td><td></td></tr><tr><td>Centrifuge 5702 R</td><td>Eppendorf</td><td>Z606936</td><td></td></tr><tr><td>Circulating water vacuum pump</td><td>Guangzhou Zhiyan Instrument Co., Ltd</td><td>SHZ-D(&lt;img alt=&quot;Equation 1&quot; src=&quot;/files/ftp_upload/64514/64514eq01.jpg&quot; style=&quot;margin: auto;&quot;/&gt;)</td><td></td></tr><tr><td>CML latex, 4% w/v</td><td>Invitrogen</td><td>C37253</td><td></td></tr><tr><td>Diatomite</td><td>Guangzhou Qishuo Chemical Co., Ltd.</td><td>/</td><td></td></tr><tr><td>Double cone rotary vacuum dryer</td><td>Jiangsu Yang-Yang Chemical Equipment Plant Inc</td><td>SZE-500T</td><td></td></tr><tr><td>enamel kettle</td><td>Jiangsu Yang-Yang Chemical Equipment Plant Inc</td><td>CS-03-002</td><td>1000L / 2000L</td></tr><tr><td>heptane</td><td>Nanjing Cook Biotechnology Co., Ltd.</td><td>General Reagent</td><td></td></tr><tr><td>HPLC</td><td>Guangzhou aoyi Technology Trading Co., Ltd</td><td>LC-2030C 3D</td><td></td></tr><tr><td>Large scale rotary evaporators</td><td>Guangzhou Xingshuo Instrument Co.,Ltd.</td><td>RE-2002</td><td></td></tr><tr><td>Low temperature and constant temperature stirring reaction bath</td><td>Guangzhou Yuhua Instrument Co., Ltd</td><td>XHDHJF-3005</td><td></td></tr><tr><td>Low temperature coolant circulating pump</td><td>Guangzhou Jincheng Scientific Instrument Co., Ltd</td><td>XHDLSB-5/25</td><td></td></tr><tr><td>Megafuge 8R</td><td>Thermo Scientific</td><td>TS-HM8R</td><td></td></tr><tr><td>N, N-Diisopropyl ethylamine (DIPEA)</td><td>Apicci Pharm</td><td>General Reagent</td><td></td></tr><tr><td>N-dimethylformamide (DMF)</td><td>Guangzhou bell Biotechnology Co., Ltd</td><td>General Reagent</td><td></td></tr><tr><td>Octanoid acid</td><td>Sigma-Aldrich</td><td>O3907</td><td></td></tr><tr><td>Pd(OAc)2</td><td>Xi&#039;an Catalyst New Materials Co.,ltd.</td><td>200704</td><td></td></tr><tr><td>Phosphate buffered saline</td><td>Sigma-Aldrich</td><td>1003335620</td><td></td></tr><tr><td>Potassium carbonate (K2CO3)</td><td>Guangzhou Zhonghua Trade Co.,Ltd.</td><td>General Reagent</td><td></td></tr><tr><td>Tert amyl alcohol</td><td>Nanjing Cook Biotechnology Co., Ltd.</td><td>General Reagent</td><td></td></tr><tr><td>tert-Butyl carbamate</td><td>Nanjing Cook Biotechnology Co., Ltd.</td><td>General Reagent</td><td></td></tr><tr><td>Thermo Mixer Heat/Cool</td><td>KASVI</td><td>K80-120R</td><td></td></tr><tr><td>toluene</td><td>Liaoning cook Biotechnology Co., Ltd</td><td>General Reagent</td><td></td></tr><tr><td>Vacuum drying oven</td><td>Guangzhou Yuhua Instrument Co., Ltd</td><td>DZF-6090</td><td></td></tr><tr><td>Water</td><td>/</td><td>/</td><td></td></tr><tr><td>Xantphos</td><td>Liaoning cook Biotechnology Co., Ltd</td><td>Asp20-44892</td><td></td></tr></tbody></table>

scaled-up preparation of an intermediate of upatinib, act051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Upatinib, a Janus kinase inhibitor drug, was developed by a biotech company to treat immune diseases. The compound tert-butyl (5-toluenesulfonyl-5h-pyrrole [2,3-b] pyrazine-2-yl) carbamate (ACT051-3) is an important intermediate of Upatinib. To date, the steady industrial production of this intermediate compound (ACT051-3) has not been reported. In this study, we described the specific synthesis method and process of the compound ACT051-3 in terms of laboratory synthesis, pilot scale-up, and industrial production. During the exploration of the process route for ACT051-3, many appropriate adjustments and improvements were made to the reaction conditions, finally leading to the successful development of the optimal industrial production process for ACT051-3. The reaction time was nearly doubled by changing the state of the potassium carbonate involved in the reaction, which greatly improved the reaction efficiency. Additionally, by introducing N,N-diisopropylethylamine (DIPEA) to the reaction, the amount of the expensive catalyst Pd(OAc)2 was reduced 2.5-fold, significantly lowering production costs, confirming the feasibility of this process route and the industrial production of ACT051-3, and satisfying market demand for this important intermediate.

This study provides the scaled-up synthesis process for the important intermediate ACT051-3 of Upatinib (Figure 1 and Figure 2). The protocol section (steps 1-3) specifically shows the gram-grade synthesis, pilot-scale kilogram-grade synthesis, and scale-up production step of the compound ACT051-2 and the intermediate ACT051-3.
In the course of exploring the optimal route for the compound ACT051-2, as shown in <strong...

Here, we present a protocol for the scaled-up synthesis of the intermediate tert-butyl (5-toluenesulfonyl-5h-pyrrole [2,3-b] pyrazine-2-yl) carbamate (ACT051-3) of Upatinib.

Upatinib, a Janus kinase inhibitor drug, was developed by a biotech company to treat immune diseases. The compound tert-butyl ...

scaled-up-preparation-of-an-intermediate-of-upatinib-act051-3

Research

JoVE Journal

Chemistry

The video describes the development of drug resistance in cancer cells by exposing cells to escalating doses of a drug after calculating IC50 values of the drug previously with MTT assay. The sample protocol describes the step-by-step process of developing drug-resistant cells.

Dose Escalation: A Method for Developing Drug Resistance in Cancer Cells

In this video, we describe a method highlighting the utility of bioluminescence assay for sensitive and rapid screening of drugs. These drugs can be tested alone or in combination to assess the synergism in their mode of action.

Cellular Bioluminescence Based Assay: A High Throughput Method for Combinatorial Drug Screening

Emergence of genetic resistance against kinase inhibitor therapy poses significant challenge for effective cancer therapy. Identification and characterization of resistant mutations against a newly developed drug helps in better clinical management and next generation drug design. Here, we describe our protocol for in vitro screening and validation of resistant mutations.

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.

Assessing Specificity of Anticancer Drugs In Vitro

We present a three-dimensional (3D) lung cancer model based on a biological collagen scaffold to study sensitivity towards non-small-cell-lung-cancer-(NSCLC)-targeted therapies. We demonstrate different read-out techniques to determine the proliferation index, apoptosis and epithelial-mesenchymal transition (EMT) status. Collected data are integrated into an in silico model for prediction of drug sensitivity.

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

A method for establishing afatinib-resistance cell lines from lung adenocarcinoma PC-9 cells was developed, and resistant cells were characterized. The resistant cells can be used to investigate epidermal growth factor receptor tyrosine kinase inhibitor-resistance mechanisms, applicable for patients with non-small cell lung cancer.

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

The present protocol describes generating 3D tumor culture models from primary cancer cells and evaluating their sensitivity to drugs using cell-viability assays and microscopic examinations.

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Silica nanoparticles were prepared using acid-catalysis of a siloxane precursor and microwave-assisted synthetic techniques resulting in the controlled growth of nanomaterials ranging from 30-250 nm in diameter. The growth dynamics can be controlled by varying the initial silicic acid concentration, time of the reaction, and temperature of reaction.

Preparation of Silica Nanoparticles Through Microwave-assisted Acid-catalysis

Learn a scalable synthesis protocol for the Upatinib intermediate ACT051-3 using optimized reaction conditions. This method offers a simple, cost-effective, and environmentally friendly approach for pharmaceutical production.

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Explore More Videos